TB-500 vs GHK-Cu for dogs
The short answer
For a healing wound, GHK-Cu topical is the lower-risk starting point: it needs no injection, carries minimal systemic exposure, and avoids the cancer question entirely. Neither compound has canine wound data — the copper tripeptide study often cited as canine was conducted in rats. TB-500 is the more relevant option for deeper soft tissue injury that a topical cannot reach, but it brings a firm contraindication in dogs with malignancy. In dogs where copper handling is a concern — Bedlington Terriers, certain Labrador lines, or any dog with liver disease — the balance shifts back toward TB-500, provided cancer has been excluded.
Side by side
| TB-500 | GHK-Cu | |
|---|---|---|
| Evidence grade | Emerging evidence | Emerging evidence |
| Route | Injectable only | Topical or injectable |
| Cancer contraindication | Contraindicated with active cancer | Avoid injectable with active cancer; topical lower concern |
| Depth of action | Systemic, reaches deep tissue | Topical acts locally; injectable systemic |
| Monitoring burden | Injection site checks | Liver values if using the injectable route |
| Full profile | TB-500 for dogs | GHK-Cu for dogs |
Safety at a glance
TB-500
TB-500 is generally well tolerated in the veterinary literature, with injection-site swelling the most common observation. The decisive safety question is not tolerance but cancer status: because the compound is associated with promoting new blood vessel growth and cell migration, it is contraindicated in dogs with active or suspected malignancy. Screening before starting is not optional. It is also banned in competitive racing and is detectable on testing.
Is TB-500 safe for dogs? →GHK-Cu
GHK-Cu used topically is among the lowest-risk options on this site — systemic absorption is minimal and long-term use is generally considered acceptable. Note that despite frequent claims otherwise, there is no canine study behind it: the often-cited Veterinary Surgery paper was conducted in rats. The injectable route carries a genuine, breed-specific hazard: Bedlington Terriers and some Labrador lines carry inherited copper storage disease, and any dog with hepatic impairment handles copper poorly. Baseline and follow-up liver values are the safeguard, and for localised problems the topical route usually makes the injectable question moot.
Is GHK-Cu safe for dogs? →Common questions
Which is better for dogs, TB-500 or GHK-Cu?+
For a healing wound, GHK-Cu topical is the lower-risk starting point: it needs no injection, carries minimal systemic exposure, and avoids the cancer question entirely. Neither compound has canine wound data — the copper tripeptide study often cited as canine was conducted in rats. TB-500 is the more relevant option for deeper soft tissue injury that a topical cannot reach, but it brings a firm contraindication in dogs with malignancy. In dogs where copper handling is a concern — Bedlington Terriers, certain Labrador lines, or any dog with liver disease — the balance shifts back toward TB-500, provided cancer has been excluded.
Can TB-500 and GHK-Cu be used together in dogs?+
Combined protocols using both compounds appear in the literature, and they are more often studied together than as alternatives. Any combination increases the difficulty of attributing an adverse effect to a specific compound, so combining should be a deliberate decision made with your veterinarian rather than a default.
Which has better evidence in dogs, TB-500 or GHK-Cu?+
TB-500 is graded emerging evidence with 5 cited studies; GHK-Cu is graded emerging evidence with 4 cited studies. Grades reflect the strength of published literature rather than an opinion about efficacy.
References
- 1.Kleinman HK, Sosne G Thymosin β4 Promotes Dermal Healing. Vitamins and Hormones, 2016. PMID 27450738
- 2.Philp D, Kleinman HK Animal studies with thymosin beta, a multifunctional tissue repair and regeneration peptide. Annals of the New York Academy of Sciences, 2010. PMID 20536453
- 3.Goldstein AL, Hannappel E, Sosne G, Kleinman HK Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opinion on Biological Therapy, 2012. PMID 22074294
- 4.Ho EN, Kwok WH, Lau MY, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma. Journal of Chromatography A, 2012. PMID 23084823
- 5.Delcourt V, Loup B, Bailly-Chouriberry L, et al. TB500/TB1000 and SGF1000: A scientific approach for a better understanding of misbranded and unapproved drugs. Drug Testing and Analysis, 2023. PMID 36482504
- 6.Canapp SO Jr, Farese JP, Schultz GS, et al. The effect of topical tripeptide-copper complex on healing of ischemic open wounds. Veterinary Surgery, 2003. PMID 14648529
- 7.Maquart FX, Bellon G, Chaqour B, et al. In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds. Journal of Clinical Investigation, 1993. PMID 8227353
- 8.Pickart L, Vasquez-Soltero JM, Margolina A GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International, 2015. PMID 26236730
- 9.Pickart L, Margolina A Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences, 2018. PMID 29986520
Where to source research peptides
Compound quality is the variable most owners underestimate. Purity, accurate peptide content, and correct labelling determine whether any published dosing figure means anything at all. Pet & Peps Research publishes third-party testing on the compounds covered in this guide and supports this site.
Educational information — not veterinary medical advice
Everything on this page is compiled from published peer-reviewed literature for educational and research purposes. It does not establish a veterinarian-client-patient relationship (VCPR) and is not a substitute for veterinary examination and diagnosis. Most compounds described here are investigational or used off-label and are not FDA-approved for these purposes in dogs. Extralabel drug use in animals requires a valid VCPR and the direct supervision of a licensed veterinarian under AMDUCA (21 U.S.C. §360b). Dosing figures are reported as they appear in the source literature and are not recommendations.